We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

COPAN DIAGNOSTICS

COPAN (which stands for COllection and Preservation for ANalysis) is a global market leader in sample collection and ... read more Featured Products: More products

Download Mobile App




Fully Automated System Transforms Pre-Analytical Handling of Urine Specimens

By LabMedica International staff writers
Posted on 14 Aug 2025

Urine specimens make up a substantial portion of a laboratory’s daily workload, yet essential pre-analytical steps such as aliquoting are often still done manually. More...

These manual processes are time-consuming, prone to error, and limit efficiency as testing volumes grow. Now, a new fully automated platform addresses these challenges by streamlining the handling of urine specimens from start to finish.

Copan Diagnostics (Murrieta, CA, USA) has introduced UriVerse, an advanced system that automates key steps, including decapping, precise aliquoting, barcode labeling, and recapping of secondary tubes. Vision-guided technology identifies containers, performs de-capping without manual sorting, and transfers up to 10 mL into as many as nine secondary tubes.

The system eliminates manual pipetting and sorting with continuous, random-access loading, cup recognition, and fully integrated labeling and capping. By automating these processes, UriVerse improves traceability, reduces variability, and integrates seamlessly into existing laboratory workflows. UriVerse is designed to meet the demands of chemistry, toxicology, and other high-volume urine testing.

UriVerse is especially suited for laboratories facing increasing volume, staff shortages, and pressure for faster turnaround times. By reducing hands-on time and minimizing errors, the system supports greater efficiency and consistency in urine testing. Its ability to handle growing specimen volumes with accuracy makes it a valuable tool for modern laboratory operations. UriVerse is designed to fit easily into existing laboratory workflows.

"With UriVerse, we offer an efficient, accurate solution to help laboratories meet rising urine testing demands while reducing variability through automation of manual pre-analytical tasks," said Fabrizio Mazzocchi, CEO of Copan Diagnostics.

Related Links:
Copan Diagnostics 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.